Clinical & Translational Oncology最新文献

{"title":"Clinical value of ENO2 in serum extracellular vesicles for the diagnosis and prognosis of diffuse large B-cell lymphoma patients.","authors":"Ruiyu Yang, Yimin Hu, Qingguo Liu, Pingping Huang","doi":"10.1007/s12094-025-04030-9","DOIUrl":"https://doi.org/10.1007/s12094-025-04030-9","url":null,"abstract":"<p><strong>Background: </strong>This study investigates the differential expression of ENO2 in serum extracellular vesicles (EVs) of patients with diffuse large B cell lymphoma (DLBCL) and its correlation with clinicopathological characteristics and prognosis.</p><p><strong>Methods: </strong>Serum samples before receiving treatment, clinicopathological characteristics, and follow-up information were collected from 78 patients with DLBCL, and 40 patients with reactive hyperplasia of lymph nodes (RH) were selected as the control group. ENO2 expression in serum EVs was detected by RT-qPCR and Western blot. The diagnostic value of ENO2 in serum EVs for DLBCL was analyzed by ROC curve. The correlation between ENO2 expression and clinicopathological data was analyzed by chi square test. The 5-year overall survival (OS) was analyzed by Kaplan-Meier method. The COX proportional hazards model was employed for analyzing prognostic risk factors of DLBCL.</p><p><strong>Results: </strong>ENO2 is highly expressed in serum EVs of DLBCL patients. ENO2 in serum EVs has moderate diagnostic efficacy for DLBCL, with a sensitivity, specificity, and AUC of 0.808, 0.725, and 0.789, respectively. ENO2 expression is closely related to ECOG score, LDH level, Ann Arbor stage, IPI, and Bcl-2. DLBCL patients with age (> 60 years), ECOG (2-4), LDH level (High), Ann Arbor stage (III + IV), IPI score (3-5), Ki-67 (≥ 70%), Bcl-2 (positive), and ENO2 protein (high expression) have lower 5-year OS. ENO2 protein (high expression), ECOG (2-4), Ann Arbor stage (III + IV), and Ki-67 (≥ 70%) are independent prognostic risk factor for DLBCL.</p><p><strong>Conclusions: </strong>ENO2 is correlated with the clinicopathological characteristics of DLBCL and is an independent prognostic risk factor.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of DNA ploidy, stroma fraction, and nucleotyping in stage IIIb colon cancer and their implications for adjuvant chemotherapy.","authors":"Weili Zhang, Yuxin Gu, Xiajuan Xue, Xudan Li, Weifeng Wang, Ruowei Wang, Jiahua He, Weihao Li, Yue Xing, Yuguang Lin, Jianhong Peng","doi":"10.1007/s12094-025-04029-2","DOIUrl":"https://doi.org/10.1007/s12094-025-04029-2","url":null,"abstract":"<p><strong>Background: </strong>DNA ploidy (P), stroma fraction (S), and nucleotyping (N), collectively known as PSN, have demonstrated prognostic accuracy in various stages of colorectal cancer (CRC). However, the prognostic value of the PSN panel in stage IIIb colon cancer patients receiving CapOX adjuvant chemotherapy remains unclear.</p><p><strong>Patients and methods: </strong>Postoperative pathological samples from stage IIIb colon cancer patients who underwent radical surgery and postoperative adjuvant chemotherapy at Sun Yat-sen University Cancer Center were retrospectively collected. Kaplan-Meier and Cox regression were performed to compare survival among subgroups of patients stratified by PSN, in order to elucidate the benefits of different durations of adjuvant CapOX chemotherapy.</p><p><strong>Result: </strong>The PSN low-risk group had the highest 5-year DFS (95.77% vs. 83.07% vs. 84.29%, P = 0.023). Multivariate Cox regression analysis identified primary tumor location (HR = 4.166, 95% CI 1.616-10.742, P = 0.003), perineural invasion (HR = 2.358, 95% CI 1.205-4.615, P = 0.012), and PSN high risk (HR = 3.830, 95% CI 1.352-10.853, P = 0.011) as independent predictors of DFS. No significant difference in 5-year DFS and overall survival (OS) was observed between patients receiving 4-7 cycles and those receiving 8 cycles of CapOX (DFS: 86.24% vs. 88.77%, P = 0.082; OS: 96.38% vs. 94.23%, P = 0.088). However, in the PSN high-risk group, completing 8 cycles of CapOX significantly improved 5-year DFS and OS compared to 4-7 cycles (DFS: 93.10% vs. 77.04%, P = 0.033; OS: 96.30% vs. 91.24%, P = 0.037). In contrast, no significant difference in DFS was observed in the IDEA (International Duration Evaluation of Adjuvant therapy)-based high-risk group (DFS: 85.85% vs. 80.75%, P = 0.062; OS: 97.56% vs. 87.05%, P = 0.598).</p><p><strong>Conclusion: </strong>The PSN panel effectively stratifies stage IIIb colon cancer, aiding in optimized adjuvant chemotherapy duration determination.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.","authors":"Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, Almudena García Castaño, Teresa Puértolas, Enrique Espinosa, Javier Medina, Lorena Bellido, Alfonso Berrocal, Margarita Majem, Rafael López Castro, Luis Antonio Fernandez, Francisco Garcia, Maria Rodriguez de la Borbolla, Salvador Martín Algarra, Iván Márquez-Rodas","doi":"10.1007/s12094-025-04018-5","DOIUrl":"https://doi.org/10.1007/s12094-025-04018-5","url":null,"abstract":"<p><strong>Background: </strong>Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.</p><p><strong>Objective: </strong>To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.</p><p><strong>Methods: </strong>We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.</p><p><strong>Results: </strong>69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).</p><p><strong>Conclusions: </strong>Our data confirms a poor outcome of AM in the Spanish population.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.","authors":"Wenwang Lang, Jiangbo Wang, Haiqing Zhao, Yulong He, Qinling Jiang, Qi Ai, Ming Ouyang","doi":"10.1007/s12094-025-04035-4","DOIUrl":"https://doi.org/10.1007/s12094-025-04035-4","url":null,"abstract":"<p><strong>Purpose: </strong>Socazolimab, in combination with chemotherapy, has been shown to prolong progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). This study is the first to evaluate its cost-effectiveness from the perspectives of both the U.S. payer and Chinese healthcare systems.</p><p><strong>Methods: </strong>A Markov state-transition model was employed to conduct an economic evaluation, incorporating clinical and economic parameters from both the U.S. and China. Baseline patient characteristics and key clinical inputs were sourced from a randomized phase 3 trial, whereas cost and utility values were derived from open-access databases and published literature. The primary outcomes assessed included quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). Model uncertainty was addressed through probabilistic sensitivity, one-way sensitivity, and scenario analyses.</p><p><strong>Results: </strong>In the base-case scenario, the addition of socazolimab to chemotherapy resulted in a marginal QALY gain of 0.09, at an incremental cost of $14,504.53, leading to an ICER of $152,228.60 per QALY. This ICER was below China's willingness-to-pay (WTP) threshold of $40,354.27 per QALY, making it not cost-effective, with an INHB of -0.26 QALYs and an INMB of -$10,523.93. In the U.S., while the incremental QALY gain remained at 0.10, the additional cost increased to $85,599.55, yielding an ICER of $878,912.80 per QALY, far exceeding that of the U.S. WTP threshold of $150,000.00, confirming its lack of cost-effectiveness.</p><p><strong>Conclusions: </strong>The combination of socazolimab with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the United States, highlighting the need for price adjustments and alternative treatment strategies to improve economic viability.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hotspots and future trends of male breast cancer: a global perspective.","authors":"Jie Hou, Hui Feng, Minheng Zhang, Dayi Wang, Haixia Fan","doi":"10.1007/s12094-025-04026-5","DOIUrl":"https://doi.org/10.1007/s12094-025-04026-5","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC), a rare disease accounting for less than 1% of all cancers in men and approximately 1% of all breast cancers globally, exhibits unique biological and clinical characteristics that distinguish it from female breast cancer (FBC). To identify the latest developments and trends in MBC research, we performed a comprehensive analysis of relevant literature and generated visual representations of the data. Building on these outcomes, we delve into the insights gained, aiming to enhance the ongoing comprehension of MBC.</p><p><strong>Methods: </strong>We conducted a search of the Web of Science Core Collection (WoSCC) for English-language articles and reviews on MBC published from 1982 to 2024. Following a rigorous dual-researcher screening process, we refined the dataset to 6802 relevant records. Subsequently, we employed Microsoft Excel for initial data organization and processing. For in-depth analysis and visualization of journal, country/region, author/institution trends, as well as keyword patterns, we utilized a combination of R Package, VOSviewer, and CiteSpace. This multi-tool approach enabled us to extract and present meaningful insights from the data.</p><p><strong>Results: </strong>MBC research has risen since 1996, with a 2024 peak at 503 publications, reflecting advances like BRCA1/2 gene discoveries. The USA leads in publications and citations, with North America and Europe being the most collaborative regions. Key journals include Breast Cancer Research and Treatment, and leading contributors are Ottini, Laura and Van Diest, Paul J. Research focuses on MBC's genetic links (e.g. BRCA mutations) and clinical features, with emerging topics like precision medicine and immunotherapy.</p><p><strong>Conclusion: </strong>MBC research has grown but remains concentrated in high-income countries. Future efforts should explore MBC's unique biology, improve diagnostic/therapeutic strategies, and involve global, interdisciplinary collaboration to enhance patient outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma.","authors":"Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel, Salih Tunbekici, Fatma Pınar Açar, Gülçin Çelebi, Burçak Karaca","doi":"10.1007/s12094-025-04024-7","DOIUrl":"https://doi.org/10.1007/s12094-025-04024-7","url":null,"abstract":"<p><strong>Background: </strong>Despite the therapeutic advances of immune checkpoint inhibitors in advanced melanoma, early identification of treatment non-responders remains a major clinical need. Dynamic changes in peripheral blood biomarkers may provide a cost-effective and non-invasive strategy to monitor treatment response during the early phase of immunotherapy.</p><p><strong>Methods: </strong>We retrospectively analyzed 70 patients with advanced melanoma treated with combination ipilimumab and nivolumab between 2017 and 2025. Dynamic changes in neutrophil-to-lymphocyte ratio (ΔNLR), lymphocyte-to-monocyte ratio (ΔLMR), platelet-to-lymphocyte ratio (ΔPLR), systemic immune-inflammation index (ΔSII), eosinophil count (ΔEosinophils), and lactate dehydrogenase (ΔLDH) were calculated as the ratio of post-treatment (prior to the third cycle) to pre-treatment (baseline) values. ROC analysis and logistic regression models assessed each biomarker's predictive value for objective response. Each delta marker was tested in a separate multivariate model adjusted for clinical covariates identified through univariate analysis.</p><p><strong>Results: </strong>Among 70 patients, 28 (40.0%) achieved an objective response. ΔNLR and ΔLMR showed the strongest discriminative performance (AUCs: 0.836 and 0.793, respectively). In multivariate models incorporating univariate-selected clinical covariates, high ΔNLR (OR = 20.3, 95% CI 4.65-88.45) and low ΔLMR (OR = 22.66, 95% CI 5.07-101.34) remained independently associated with non-response (both p < 0.001). These biomarkers also improved the predictive performance of the clinical model (ΔAUC: + 7.7%).</p><p><strong>Conclusions: </strong>Routine assessment of early dynamic changes in ΔNLR and ΔLMR after two cycles of ipilimumab-nivolumab therapy can enable timely identification of non-responders in advanced melanoma, allowing early discontinuation or switching of treatment to avoid unnecessary toxicity and cost. These biomarkers rely on standard blood counts and are readily applicable in clinical practice. Nevertheless, the retrospective single-center design and moderate sample size limit the generalizability of our findings, and prospective validation in larger, independent cohorts is warranted.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking risk in low-suspicion thyroid nodules: clinical and sonographic predictors of malignancy in TIRADS 3, a retrospective single-center study.","authors":"Dayana Torres-Cuenca, Juan Eduardo Ortiz, Fabricio González-Andrade","doi":"10.1007/s12094-025-04034-5","DOIUrl":"https://doi.org/10.1007/s12094-025-04034-5","url":null,"abstract":"<p><strong>Background: </strong>Thyroid nodules categorized as TIRADS 3 are typically considered low risk for malignancy (estimated < 5%) under the 2017 ACR TI-RADS guidelines. However, the real-world application of these criteria may vary, with many TIRADS 3 nodules undergoing fine-needle aspiration (FNA) despite recommendations for surveillance. This study aimed to identify clinical and ultrasonographic predictors of malignancy in TIRADS 3 nodules to enhance risk stratification.</p><p><strong>Methods: </strong>This retrospective, single-center study included 200 patients aged 18-65 years with ultrasound-confirmed TIRADS 3 thyroid nodules who underwent FNA between January 2021 and December 2022. Although ACR guidelines recommend biopsy for nodules ≥ 2.5 cm, FNA was also performed in smaller nodules presenting with high-risk features such as capsule bulging or central-peripheral vascularity. Data were collected from anonymized hospital records. Multivariate logistic regression was used to identify independent predictors of malignancy.</p><p><strong>Results: </strong>The malignancy rate was 20%, exceeding the expected threshold for TIRADS 3 nodules. Capsule expansion (OR 18.50, p < 0.001), central-peripheral vascularity (OR 4.99, p = 0.004), and a family history of thyroid cancer (OR 13.08, p = 0.001) were identified as significant predictors. All malignancy diagnoses were based on cytological findings (Bethesda V/VI), with no histopathologic confirmation available.</p><p><strong>Conclusion: </strong>Certain TIRADS 3 nodules may possess a higher malignancy risk than traditionally assumed. Incorporating additional ultrasound features and clinical context may improve diagnostic accuracy. Future prospective studies with histopathological confirmation are warranted to validate these predictors.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma lipidomics profiling to identify signatures of pediatric medulloblastoma.","authors":"Zhengyuan Shi, Chunjing Yang, Xiqiao Xu, Wanshui Wu, Li Bao","doi":"10.1007/s12094-025-04008-7","DOIUrl":"https://doi.org/10.1007/s12094-025-04008-7","url":null,"abstract":"<p><strong>Background: </strong>Medulloblastoma is similar to other common tumors in the posterior cranial fossa of children in terms of the onset and clinical manifestations. Still, its main treatment methods, surgical methods and prognosis are quite different. Therefore, there is an urgent need for finding biomarkers for differential diagnosis.</p><p><strong>Purpose: </strong>The purpose of this study was to identify new lipids and differential metabolic pathways by analyzing the significantly different lipids present in the plasma of children with medulloblastoma in comparison to those with other intracranial tumors.</p><p><strong>Methods: </strong>In this study, 35 patients with medulloblastoma and 32 matched controls were enrolled. Plasma samples and medical records were collected, and untargeted lipidomics analyses were performed using UHPLC-MS/MS.</p><p><strong>Results: </strong>A total of 97 differential lipids in the plasma of children with medulloblastoma were identified. Seven differential lipids could be potentially useful in medulloblastoma detection and a diagnostic model was established. The metabolic pathway analysis showed that there were significant differences in patients with medulloblastoma in terms of glycerophospholipid metabolism metabolism, sphingolipid metabolism and linoleic acid metabolism pathways.</p><p><strong>Conclusion: </strong>The difference in plasma lipid markers between medulloblastoma and other intracranial tumors screened in this study may be useful to support and improve the differential diagnosis of medulloblastoma in children.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of HER2 levels expression through HER2 mRNA PCR vs immunohistochemistry (IHC) in hormone receptor positive (HR+)/HER2 negative (HER2-) early breast cancer.","authors":"Alfonso López de Sá, Julia Tejerina, Marta Amann, Pablo Ballestín, Beatriz González, Alejandro Pascual, Cristina Díaz Del Arco, Vanesa García-Barberán, Mateo Paz-Cabezas, Alicia De Luna, José Ángel García-Sáenz, Fernando Moreno","doi":"10.1007/s12094-025-03999-7","DOIUrl":"https://doi.org/10.1007/s12094-025-03999-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the correlation between HER2 expression levels measured by HER2 mRNA using Oncotype DX and by immunohistochemistry (IHC) in hormone receptor-positive (HR+) and HER2-negative (HER2-) early breast cancer. In addition, we assessed whether low HER2 expression is associated with distinct clinicopathological characteristics and prognosis in our series.</p><p><strong>Methods: </strong>We conducted a retrospective study that included 500 patients diagnosed with stage I-III HR+/HER2- breast cancer who underwent surgery and had Oncotype DX recurrence score determined between 2009 and 2023 at Hospital Clínico San Carlos, Madrid, Spain. HER2 mRNA levels obtained through Oncotype DX were compared across IHC groups (HER2 0+, HER2 1+, HER2 2+/ISH-negative). Event-free survival (EFS) was analyzed according to HER2 expression.</p><p><strong>Results: </strong>Although HER2 mRNA levels increased with higher IHC HER2 categories, variability and overlap were observed between subgroups. Median Oncotype DX recurrence scores also rose slightly across HER2 IHC groups but did not reach statistical significance. EFS did not differ between HER2 expression levels.</p><p><strong>Conclusions: </strong>We found that HER2 mRNA measurement by Oncotype DX provides a quantitative approach to assess HER2 expression. However, its results overlap within traditional IHC categories. While HER2-low classification may have therapeutic implications for new antibody-drug conjugates, its prognostic relevance appears limited. Further studies are needed to improve HER2 quantification methods for improved clinical decision-making.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis.","authors":"Zhi Li, Juan Luo, Lihua Peng, Bangqiang Wu, Zebo Yu","doi":"10.1007/s12094-025-04028-3","DOIUrl":"10.1007/s12094-025-04028-3","url":null,"abstract":"<p><strong>Purpose: </strong>Emerging evidence suggests an association between the systemic immune-inflammation index (SII) and the survival outcomes of individuals with hepatocellular carcinoma (HCC). However, existing research findings are inconsistent, and no definitive conclusions have been reached. This research aimed to explore the predictive accuracy of the SII in patients with HCC.</p><p><strong>Methods: </strong>Numerous databases, encompassing PubMed, Embase, Web of Science, and Cochrane Library, were thoroughly retrieved from the database inception until January 14, 2025, to identify studies on the correlation between SII and survival outcomes in HCC. Studies were screened according to pre-established eligibility criteria. The primary endpoints included overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS), which were appraised via hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).</p><p><strong>Results: </strong>39 high-quality cohort studies involving 47 comparison groups were included in this analysis. As proven by the aggregated data, increased SII was significantly linked to shorter OS (HR = 1.64, 95% CI: 1.45-1.85; p < 0.00001), RFS (HR = 1.68, 95% CI: 1.44-1.96; p < 0.00001), and PFS (HR = 1.48, 95% CI: 1.20-1.82; p = 0.0002) in individuals with HCC. Furthermore, subgroup analyses revealed that age, region, intervention strategy, and SII thresholds affected the validity of SII for predicting the prognosis of HCC.</p><p><strong>Conclusion: </strong>In HCC patients treated with monotherapy or combination therapy, a higher SII before treatment is significantly associated with shorter OS, RFS, and PFS. SII may serve as an important biological indicator for assessing the prognosis of HCC, providing a critical reference for the scientific and systematic treatment of HCC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}